IGFBP3 and myeloid sarcoma: While elevated levels of IGFBP-3 in the Hosback et al. [16] study was only observed in MS patients under INF-β treatment, reduced values of IGFBP-3 were mentioned in patients with severe stages of MS and with a high index of disability in Akcali et al. and Wilczak et al. [12, 24] studies, respectively.